RESEARCH MEDICATION USE OF TYPE 2 DIABETES MEDICATIONS IN PATIENTS WITH HEART FAILURE AT VINH LONG GENERAL HOSPITAL IN 2024-2025
Main Article Content
Abstract
Background: Diabetes is a significant global issue. Among the many complications of diabetes, there is increasing concern about the accompanying heart failure. Objectives: To determine the proportion of medicines and glycemic control for type 2 diabetes mellitus in patients with heart failure at Vinh Long General Hospital in 2024-2025. Materials and methods: A cross-sectional descriptive study was conducted on 107 patients diagnosed with type 2 diabetes and heart failure at the Department of Cardiology during their hospitalization. Results: A total of 107 patients were included in the study, the rates of heart failure classification showed that HFrEF was 40.2%, HFpEF was 46.7%, and HFmrEF was the lowest at 13.1%. Insulin types accounted for the highest proportion of glucoselowering agents at 48.6%. Monotherapy with metformin represented 17.8%; combinations of metformin with gliclazide and vildagliptin accounted for 1.9%, metformin with insulin was 8.4%, and metformin with dapagliflozin was 13.1%. Conclusions: The rate of using treatment regimens containing metformin and insulin was the highest among the main diabetes medications for patients with type 2 diabetes and heart failure (48.6% used insulin and 43% used metformin for treatment).
Keywords
Heart failure, diabetes, metformin, insulin
Article Details
References
2. Huang W., R. Zhao. Clinical outcomes in type 2 diabetes patients with chronic heart failure treated with metformin: a meta-analysis. Endocrine. 2025. 87(2), 436-447, doi:
10.1007/s12020-024-04025-6.
3. American Diabetes Association. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024. 47(Suppl 1), S20-s42, doi: 10.2337/dc24-S002.
4. Marx N., et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023. 44(39), 4043-4140 , doi: 10.1093/eurheartj/ehad 192.
5. Castro Conde A., et al. Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes. J Clin Med. 2023. 12(12) , doi: 10.3390/jcm 12123925.
6. Arnold S.V., et al. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). Am Heart J. 2018. 203, 25-29 , doi: 10.1016/j.ahj. 2018.05.016.
7. Nguyễn Thị Huỳnh Mai, Đặng Duy Khánh. Tình hình sử dụng thuốc điều trị đái tháo đường tuýp 2 trên bệnh nhân suy giảm chức năng thận tại Bệnh viện Đa khoa thành phố Cần Thơ năm 2020-2021. Tạp chí Y Dược học Cần Thơ. 2021(43), 110-117.
8. Đỗ Văn Doanh,Nguyễn Hồng Hạnh, Đinh Thị Thu. Thực trạng tuân thủ điều trị của người bệnh đái tháo đường type 2 ngoại trú tại bệnh viện tỉnh Quảng Ninh năm 2016. Tạp chí Khoa học Điều dưỡng. 2019. 2(2), 14-21.
9. Nguyễn Thị Thùy Trang,Phạm Ngọc Thủy Tiên, Hoàng Thy Nhạc Vũ. Phân tích chi phí trực tiếp y tế trong điều trị đái tháo đường type 2 tại Bệnh viện Quận 8 Thành phố Hồ Chí Minh giai đoạn 2019-2021. Tạp chí Y học Việt Nam. 2022. 514(1), 123-127.
10. Zinman B., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med. 2015. 373(22), 2117-28 , doi: 10.1056/NEJMoa 1504720.
11. Bộ Y tế. Hướng dẫn chẩn đoán và điều trị đái tháo đường típ 2 ban hành kèm theo Quyết định số 5481/QĐ-BYT ngày 30 tháng 12 năm 2020. 2020, 1-37.
12. Tseng C.H. Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis. J Am Heart Assoc. 2019. 8(21) , e011640, doi: 10.1161/jaha. 118.011640.
13. Khan M.S., et al. Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. JACC Heart Fail. 2022. 10(3), 198-210, doi:
10.1016 /j.jchf. 2021.11.001.
14. Benes J., et al. Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF). Sci Rep. 2022. 12(1), 13038, doi:
10.1038/s41598-022-17327-4.
15. Wang J., et al. The Association Between Metformin Treatment and Outcomes in Type 2 Diabetes Mellitus Patients With Heart Failure With Preserved Ejection Fraction: A Retrospective Study.
Front Cardiovasc Med. 2021. 8 , 648212, doi: 10.3389/fcvm. 2021.648212.